3BNC117-LS First-in-Human Phase 1 Study

Phase 1 Completed 43 enrolled Rockefeller University

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single administration of 3BNC117-LS.

Timeline

Start: 2017-09-13
Primary completion: 2020-12-31
Completion: 2020-12-31

Publications

Valente PK, Wu Y, Cohen YZ, Caskey M, Meyers K. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. Clin Trials. 2021 Feb;18(1):17-27. doi: 10.1177/1740774520948042. Epub 2020 Aug 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Teropavimab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Teropavimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Teropavimab	Monoclonal antibody	30 mg/kg	Intravenous
Subject	Teropavimab	Monoclonal antibody	150 mg	Intravenous
Subject	Teropavimab	Monoclonal antibody	300 mg	Intravenous

3BNC117-LS First-in-Human Phase 1 Study

Summary

Timeline

Publications

Drugs

Indications